Update date: February 1, 2024

Group No. 7: Immunoallergic diseases

CHLORPHENAMINE

Clue	Description	Indications	Route of administration and dosage
010.000.0402.00	TABLET Each tablet contains: Chlorphenamine maleate 4.0 mg. Package with 20 tablets.	Immediate of hypersensitivity reactions.	Oral. Adults and kids older than 12 years old: 4 mg every 6 to 8 hours. Maximum dose: 24 mg/day.
010.000.0408.00	SYRUP Each milliliter contains: Chlorphenamine maleate 0.5 mg. Container with 60 mL.		Oral. Children: 6 to 12 years: 2 mg every 6 hours. Maximum dose: 12 mg/day. 2 to 6 years: 1 mg every 6 hours. Maximum dose: 6 mg/day.

Generalities

It competes with histamine for H1 receptor sites on effector cells.

Risk in Pregnancy b

Adverse effects

Drowsiness, restlessness, anxiety, fear, tremors, seizures, weakness, muscle cramps, vertigo, dizziness, anorexia, nausea, vomiting, diplopia, diaphoresis, chills, palpitations, tachycardia; dry mouth, nose and throat.

Contraindications and Precautions

Contraindications: Hypersensitivity to the drug, closed-angle glaucoma, peptic ulcer, pyloro-duodenal obstruction, systemic arterial hypertension, prostatic hypertrophy, bladder neck obstruction, chronic bronchial asthma.
Precautions: Children under 2 years.

Interactions

Concomitant administration with antihistamines, alcoholic beverages, tricyclic antidepressants, barbiturates or other central nervous system depressants increases its sedative effect.

SODIUM CHROMOGLYCATE

Clue	Description	Indications	Route of administration and dosage
010.000.0464.00	AEROSOL SUSPENSION Each inhaler contains: Disodium Cromoglycate 560 mg. Container with spacer for 112 doses of 5 mg.	Bronchial asthma.	Inhalation. Adults and children over 2 years: 2 inhalations every 6 hours.

Generalities

It inhibits degranulation of sensitized mast cells, which occurs after exposure to specific antigens. It also inhibits the release of histamine and the slow reaction substance of anaphylaxis.

Risk in Pregnancy b

Adverse effects

Cough, bronchospasm, pharyngeal irritation.

Contraindications and Precautions

Contraindications: Hypersensitivity to the drug. Precautions: Children under 2 years.

Interactions

None of clinical importance.

DIPHENHYDRAMINE

Clue	Description	Indications	Route of administration and dosage

010.000.0405.00	SYRUP Each 100 milliliters contain: Diphenhydramine hydrochloride mg. 250 Container with 60 mL.	Immediate hypersensitivity reactions. of	Oral. Adults: 25 to 50 mg every 6 to 8 hours. Maximum dose: 100 mg/kg body weight/day. Children from 3 to 12 years: 5 mg/kg body weight/day, divided every 6 to 8 hours. Maximum dose: 50 mg/kg body weight/day.
010.000.0406.00	INJECTABLE SOLUTION Each vial contains: Diphenhydramine hydrochloride 100 mg. Container with 10 mL vial.		Intramuscular: Adults and kids older than 12 years old: 10 to 50 mg every 8 hours. Maximum dose 400 mg/day. Children from 3 to 12 years: 5 mg/kg/day every 6 hours Maximum dose 300 mg/day.

Generalities

It competes with histamine for H1 receptor sites on effector cells.

Risk in Pregnancy

b

Adverse effects

Drowsiness, restlessness, anxiety, fear, tremors, seizures, weakness, muscle cramps, vertigo, dizziness, anorexia, nausea, vomiting, diplopia, diaphoresis, chills, palpitations, tachycardia; dry mouth, nose and throat.

Contraindications and Precautions

Contraindications: Hypersensitivity to the drug, closed-angle glaucoma, peptic ulcer, pyloroduodenal obstruction, arterial hypertension, prostatic hypertrophy, bladder neck obstruction, chronic bronchial asthma.
Precautions: Children under 2 years.

Interactions

Concomitant administration with antihistamines, alcoholic beverages, tricyclic antidepressants, barbiturates or other central nervous system depressants increases its sedative effect.

HYDROCORTISONE

Clue	Description	Indications	Route of administration and dosage
010.000.0474.00	INJECTABLE SOLUTION Each vial contains: Hydrocortisone sodium succinate equivalent to 100 mg of hydrocortisone. Package with 50 vials and 50 ampoules with 2 mL of diluent.	Suprarrenal insufficiency. Shock states. Autoimmunity. Asthmatic status.	Intravenous or intramuscular. Adults: Initial: 100 to 250 mg (intramuscular). In shock: 500 to 2000 mg every 2 to 6 hours. Children: 20 to 120 mg/m2 of body surface area/day, every 12 to 24 hours, for three days.

Generalities

Fast-acting corticosteroid with anti-inflammatory properties, reduces the immune response.

Risk in Pregnancy

c

Adverse effects

Immunodepression, peptic ulcer, psychiatric disorders, acne, glaucoma, hyperglycemia, pancreatitis, growth arrest in children, osteoporosis.

Contraindications and Precautions

Contraindications: Hypersensitivity to the drug, systemic mycosis.
Precautions: Liver disease, osteoporosis, diabetes mellitus, peptic ulcer.

Interactions

With barbiturates, phenytoin and rifampicin its therapeutic effect decreases. With acetylsalicylic acid, the risk of peptic ulcer and gastrointestinal bleeding increases.

HYDROXIZINE

Clue	Description	Indications	Route of administration and dosage
040.000.0409.00	DRAGEE OR TABLET Each dragee or tablet contains: Hydroxyzine hydrochloride 10 mg. Package with 30 dragees or tablets.	Anxiety and tension emotional. Hyperkinesia. Urticaria. Induction of preoperative postoperative and sedation.	Oral. Adults: 25-50 mg daily in divided doses each 8 hours. Children: 2 mg/kg body weight/day in divided doses every 6 hours.

Generalities

Antagonist of H1 receptors on effector cells. It moderates histamine-mediated responses, particularly on bronchial smooth muscle, digestive system, blood vessels, and depresses the central nervous system.

Risk in Pregnancy x

Adverse effects

Drowsiness, dry mouth, nausea, vomiting, dizziness.

Contraindications and Precautions

Contraindications: Hypersensitivity to the drug, myasthenia, lassitude.
Precautions: Bronchial asthma, children under 2 years of age.

Interactions

With central nervous system depressants its adverse effect is enhanced.

LORATADINE

Clue	Description	Indications	Route of administration and dosage
010.000.2144.00	TABLET OR DRAGEE Each tablet or dragee contains: Loratadine 10 mg. Package with 20 tablets or dragees.	Immediate of hypersensitivity reactions.	Oral. Adults and children over 6 years old: 10 mg every 24 hours. Children from 2 to 6 years: 5 mg every 24 hours.

Generalities

Selective antagonist of H1 receptors.

Risk in Pregnancy b

Adverse effects

Headache, nervousness, dryness of the mucosa, nausea, vomiting, urinary retention.

Contraindications and Precautions

Contraindications: Hypersensitivity to the drug.
Precautions: Liver failure.

Interactions

With ketoconazole, erythromycin or cimetidine its plasma concentrations increase.

BETAMETHASONE

Clue	Description	Indications	Route of administration and dosage
	INJECTABLE SOLUTION Each vial or vial contains: Betamethasone sodium phosphate 5.3 mg equivalent to 4 mg of betamethasone.	Suprarrenal insufficiency. Inflammatory alterations. State of shock. Asthmatic status.	Intramuscular, intravenous, intra-articular. Adults: 0.5 to 8 mg/kg body weight/day. Children:

010.000.2141.00 Container with a vial or a vial with 1 mL.			30 to 120 µg/kg body weight, every 12 to 24 hours.

Generalities

Corticosteroid with anti-inflammatory properties, reduces the immune response.

Risk in Pregnancy c

Adverse effects

Immunodepression, peptic ulcer, psychiatric disorders, acne, glaucoma, hyperglycemia, pancreatitis, growth arrest in children, osteoporosis.

Contraindications and Precautions

Contraindications: Hypersensitivity to the drug, systemic mycosis.
Precautions: Liver disease, osteoporosis, diabetes mellitus, peptic ulcer.

Interactions

With barbiturates, phenytoin and rifampicin its therapeutic effect decreases. With acetylsalicylic acid, the risk of peptic ulcer and gastrointestinal bleeding increases.

EPINASTINE

Clue	Description	Indications	Route of administration and dosage
010.000.3143.00	TABLET Each tablet contains: Epinastine hydrochloride 20 mg. Package with 10 tablets.	Allergic rhinitis. Urticaria. Eczema. Atopic dermatitis. Bronchial asthma prophylaxis.	Oral. Adults and kids older than 12 years old: One tablet every 24 hours.

Generalities

Tetracyclic derivative of guanidine, H1 antihistamine with antagonist action on leukotrienes, serotonin and other chemical mediators.

Risk in Pregnancy c

Adverse effects

Fatigue, headache, dry mouth, slight dizziness, nervousness.

Contraindications and Precautions

Contraindications: Hypersensitivity to the drug. Pyloroduodenal obstruction, Narrow-angle glaucoma, Prostatic hypertrophy, Asthma.
Precautions: In children under 5 years of age and people who operate vehicles or machinery that requires precision.

Interactions

Monoamine oxidase inhibitors intensify antihistamine effects. Enhances the effects of alcoholic beverages and central nervous system depressants. Inhibits the effect of oral anticoagulants.

FEXOPHENADINE

Clue	Description	Indications	Route of administration and dosage
010.000.3146.00	COMPRESSED Each tablet contains: Fexofenadine hydrochloride 180 mg. Package with 10 tablets.	Allergic rhinitis. Chronic idiopathic urticaria.	Oral. Adults and people over 12 years old: Allergic rhinitis: 120 mg per day. Chronic idiopathic urticaria: 180 mg per day. Children from 6 to 11 years: 60 mg per day divided into two doses.

Generalities

Peripheral H1 receptor antagonist, selective antihistamine.

Risk in Pregnancy C

Adverse effects

Headache, dizziness, nausea, drowsiness.

Contraindications and Precautions

Contraindications: Hypersensitivity to the drug.
Precautions: Kidney failure.

Interactions

With antacids its effectiveness decreases.

FLUTICASONE

Clue	Description	Indications	Route of administration and dosage
010.000.5646.00	NASAL AEROSOL SUSPENSION Each shot provides: Fluticasone furoate 27.5 µg. Container with 120 shots.	Seasonal allergic rhinitis and perennial.	Nasal. Adults and people over 12 years of age. Initial dose 2 shots in each nostril, once a day (total daily dose of 110 µg). Once adequate symptom control is achieved, reduce dosage to one shot in each nostril, once daily (total daily dose of 55 µg), as maintenance therapy.

Generalities

It reduces irritation and inflammation of the nose and its cavities, consequently relieving the sensation of blocked nose, runny nose, itching and sneezing.

Risk in Pregnancy C

Adverse effects

Epistaxis

Contraindications and Precautions

Contraindications: Hypersensitivity to the drug.
Precautions: Severe hepatic impairment, simultaneous administration with ritonavir. Do not use the product in patients with glaucoma, atrophic rhinitis, microbial, fungal and viral infection.

Interactions

No drug or other interactions have been observed.

UNMODIFIED IMMUNOGLOBULIN G

Clue	Description	Indications	Route of administration and dosage
	INJECTABLE SOLUTION Each vial with lyophilisate or solution contains: Unmodified immunoglobulin G 6 g.	Immunodeficiencies primary and secondary. Hypogammaglobulinemia. Agammaglobulinemia. Thrombocytopenic purpura. Guillain Barre syndrome.	Intravenous infusion. Adults: Immunodeficiency: 0.2 to 0.4 g/kg body weight/day, at 3-week intervals. Sepsis: 0.4 to 1 g/kg body weight/day for one to four days, or at intervals of 1 to 2 weeks. Purpura and Guillain-Barré: 0.4 g/kg body weight/day, for 5 days.
010.000.5240.00	Container with a 120 mL vial.		
010.000.5240.01	Container with vial and bottle with 200 mL of diluent. With infusion set with disposable adapter and needle.		
	INJECTABLE SOLUTION Each vial contains: Unmodified immunoglobulin G 5g.		
010.000.5244.00	Container with a 100 mL vial.		
010.000.5244.01	Container with a vial with lyophilisate and a vial with 90 a 100 mL of diluent.		

Generalities

Immunoglobulin that is used to replace or replace natural antibodies.

Risk in Pregnancy

d

Adverse effects

Anaphylactic reaction, hyperemia, headache, nausea, vomiting, hypotension and tachycardia.

Contraindications and Precautions

Contraindications: Hypersensitivity to human immunoglobulins, especially in patients with Ig A antibodies.

Interactions

Decreases the effectiveness of active immunization; Therefore, the patient should not be vaccinated while using the immunoglobulin.

HUMAN IMMUNOGLOBULIN

Clue	Description	Indications	Route of administration and dosage
	INJECTABLE SOLUTION Each vial contains: Intravenous normal human immunoglobulin 2.5 g.	Primary humoral immunodeficiency (PHI): Congenital agamaglobulinemia. X-linked gammaglobulinemia. Wiskott-Aldrich syndrome. Idiopathic thrombocytopenic purpura (ITP). Inflammatory demyelinating polyneuropathy chronicle (CIDP).	Intravenous. Children and adults: For IHP. 300 to 600 mg/Kg/dose. Initial infusion rate 1 mg/Kg/minute. Maintenance infusion rate (if tolerated) 8 mg/Kg/minute. Every 3-4 weeks. For PTI: 2 g/kg/dose. Initial infusion rate 1mg/Kg/minute. Maintenance infusion rate (if tolerated) 8 mg/Kg/minute. is For PDIC: Loading dose: 2 g/Kg; maintenance dose: 1 g/Kg. Initial infusion rate 2 mg/Kg/minute. Maintenance infusion rate 8 mg/Kg/minute (if tolerated). Every 3 weeks.
010.000.5696.00	Container with a 25 mL vial.		
	INJECTABLE SOLUTION Each vial contains: Intravenous normal human immunoglobulin 5.0 g.		
010.000.5697.00	Container with a 50 mL vial.		
	INJECTABLE SOLUTION Each vial contains: Intravenous normal human immunoglobulin 10.0 g.		
010.000.5698.00			

	Container with a 100 mL vial.		

Generalities

It is used in patients with primary or secondary immunodeficiency as replacement therapy, to provide passive immunity by increasing antibody titers.

Risk in Pregnancy C

Adverse effects

Hypersensitivity reactions, nausea, vomiting, abdominal pain, arterial hypotension, tachycardia, dizziness, headache, fever.

Contraindications and Precautions

Contraindications: Hypersensitivity to the biological, Ig A deficiency.
Precautions: Do not administer intramuscularly or subcutaneously. With caution in patients with a history of cardiovascular disease or thrombotic episodes, renal failure. Renal dysfunction, acute renal failure, osmotic nephrosis, and death may be associated with human intravenous immunoglobulin products in predisposed patients. Administer intravenous human normal immunoglobulin at the lowest concentration available and the lowest infusion rate.

Interactions

Do not mix with other drugs or liquids for intravenous infusion or with live virus vaccines such as measles, mumps, rubella.

NORMAL SUBCUTANEOUS HUMAN IMMUNOGLOBULIN

Clue	Description	Indications	Route of administration and dosage
010.000.5641.00	INJECTABLE SOLUTION Each vial contains: Normal human immunoglobulin 1650 mg. Container with a 10 mL vial.	replacement therapy in immunodeficiencies.	Subcutaneous or intramuscular. In exceptional cases, where subcutaneous administration cannot be applicable, low doses may be administered intramuscularly. Adults and children: Syringe administration: Loading dose of at least 0.2 to 0.5 g/kg body weight. After a sustained state of IgG levels are achieved, a maintenance dose should be administered at repeated intervals to achieve a cumulative monthly dose of the order of 0.4 to 0.8 g/kg.
010.000.5642.00	INJECTABLE SOLUTION Each vial contains: Normal human immunoglobulin 3300 mg. Container with a 20 mL vial.		
010.000.6025.00	INJECTABLE SOLUTION Each vial contains: Human normal immunoglobulin 1 g Container with a 5 mL vial.		Subcutaneous. Adults and children: Syringe administration: Loading dose of at least 0.2 to 0.5 kg body weight. After a sustained state of IgG levels are achieved, a maintenance dose should be administered at repeated intervals to achieve a cumulative monthly dose of the order of 0.4 to 0.8 g/kg body weight.
010.000.6026.00	INJECTABLE SOLUTION Each vial contains: Human normal immunoglobulin 2 g Container with a 10 mL vial.		
010.000.6027.00	INJECTABLE SOLUTION Each vial contains: Human normal immunoglobulin 4 g Container with a 20 mL vial.		

Generalities

It provides passive immunity by increasing the levels of antibodies mainly of the IgG type with a broad spectrum of antibodies against infectious agents.

Risk in Pregnancy b

Adverse effects

Allergic reaction, hypotension, chills, headache, nausea, vomiting, fever, arthralgia and moderate back pain may occur occasionally.

Contraindications and Precautions

Contraindications: Hypersensitivity to the biological.
Precautions: Patients with hyperprolinemia. Subcutaneous Human Normal Immunoglobulin should not be administered intravascularly.

Interactions

Administration of immunoglobulin may reduce the effectiveness of live attenuated vaccines, such as measles, rubella, mumps, and chickenpox, for a period of at least six weeks and up to three months.
After the administration of this medicine, an interval of three months should elapse before the administration of live attenuated virus vaccines. In the case of measles, this reduction in effectiveness can persist for up to a year. Therefore, patients receiving measles vaccine should have their antibody levels checked.

KETOTIFENE

Clue	Description	Indications	Route of administration and dosage
010.000.0463.00	ORAL SOLUTION Each 100 mL contains: Fumarate ketotifen acid equivalent to 20 mg ketotifen. Container with 120 mL and dispenser.	Immediate of hypersensitivity reactions.	Oral. Children over 2 years: 0.4 to 0.6 mg every 12 hours.

Generalities

It inhibits the release of histamine, leukotrienes and other chemical mediators that intervene in hypersensitivity reactions, by blocking the transport of calcium in the cell membrane of mast cells. It has no effect on acute asthmatic attack.

Risk in Pregnancy c

Adverse effects

Drowsiness, sedation, dry mouth, excitement, nervousness, insomnia.

Contraindications and Precautions

Contraindications: Hypersensitivity to the drug.

Interactions

Enhances the effects of alcoholic beverages and central nervous system depressants.

LEVOCETYRIZINE

Clue	Description	Indications	Route of administration and dosage
010.000.3150.00	TABLET Each tablet contains: Levocetirizine dihydrochloride 5 mg. Package with 20 tablets.	Seasonal allergic rhinitis. Perennial allergic rhinitis. Chronic idiopathic urticaria.	Oral. Adults and children over 6 years old: 5 mg every 24 hours.

Generalities

Active (R) enantiomer of cetirizine. Potent and selective antagonist of H1 receptors .

Risk in Pregnancy c

Adverse effects

Headache, drowsiness, dry mouth, fatigue, asthenia, abdominal pain.

Contraindications and Precautions

Contraindications: Hypersensitivity to the drug.
Precautions: In moderate to severe renal failure, in galactose intolerance, Lapp lactase deficiency and in glucose-galactose malabsorption.

Interactions

None of clinical importance

LORATADINE

Clue	Description	Indications	Route of administration and dosage
010.000.2145.00	SYRUP Each 100 mL contains: Loratadine 100 mg. Container with 60 mL and dispenser.	Immediate of hypersensitivity reactions.	Oral. Adults and children over 6 years old: 10 mg every 24 hours. Children from 2 to 6 years: 5 mg every 24 hours.

Generalities

Selective antagonist of H1 receptors.

Risk in Pregnancy b

Adverse effects

Headache, nervousness, dryness of the mucosa, nausea, vomiting, urinary retention.

Contraindications and Precautions

Contraindications: Hypersensitivity to the drug.
Precautions: Liver failure.

Interactions

With ketoconazole, erythromycin or cimetidine its plasma concentrations increase.

MOMETASONE

Clue	Description	Indications	Route of administration and dosage
010.000.4141.00	SUSPENSION FOR INHALATION Each 100 mL contains: Furoate mometasone monohydrate equivalent to 0.050 g of furoate mometasone anhydrous. Nebulizer container with 18 mL and dosing valve (140 nebulizations of 50 µg each).	Allergic rhinitis.	Nasal. Adults and children: One to two nebulizations every 24 hours. Do not exceed 200 µg/day.

Generalities

Synthetic glucocorticoid that inhibits the inflammatory response by blocking: expression of histamine, leukotrienes, interleukins (1, 4, 5, 6 and 8), gamma interferon and tumor necrosis factor.

Risk in Pregnancy c

Adverse effects

Epistaxis, pharyngitis, nasal burning and irritation, headache.

Contraindications and Precautions

Contraindications: Hypersensitivity to the drug.

Interactions

None of clinical importance.